Chlorthalidone Dosing and Monitoring
For hypertension, chlorthalidone should be initiated at 12.5-25 mg once daily, with a maximum dose of 50 mg daily; it is available in 25 mg and 50 mg tablets, and you must monitor electrolytes (particularly potassium), renal function, glucose, and uric acid shortly after initiation and periodically thereafter.
Available Strengths
Chlorthalidone tablets are available in two strengths 1:
- 25 mg tablets (pale yellow, round)
- 50 mg tablets (pale green, round, scored)
Maximum Dose
The maximum effective dose is 50 mg once daily for hypertension 2, 1. While the FDA label mentions doses up to 100 mg daily for hypertension and up to 200 mg for edema 1, doses above 50 mg provide minimal additional blood pressure reduction but significantly increase adverse metabolic effects 2. The evidence from major trials (ALLHAT, SHEP) used 12.5-25 mg doses with superior safety profiles 2, 3.
Dosing Recommendations
For Hypertension:
- Initial dose: 12.5-25 mg once daily 2, 4, 1
- If inadequate response after suitable trial: increase to 50 mg once daily 1
- Optimal dosing is 12.5-25 mg/day based on clinical outcome trials showing this range balances efficacy with minimal adverse effects 2, 4
- Doses above 50 mg rarely increase effectiveness 1
Special Populations:
- Pediatric patients (≥6 years): Initial 0.3 mg/kg/day, maximum 2 mg/kg/day up to 50 mg/day 5
- Advanced CKD (Stage 4): Start 12.5 mg daily, titrate every 4 weeks to maximum 50 mg if needed 6, 7
Critical Monitoring Parameters
You must monitor the following shortly after initiating therapy and periodically thereafter 5, 3:
Electrolytes (Most Important):
Potassium: Chlorthalidone carries a 3-fold higher risk of hypokalemia compared to hydrochlorothiazide 3, 8
Sodium: Monitor for hyponatremia, which occurs more frequently than with hydrochlorothiazide (adjusted HR 1.68) 8
Magnesium: Chlorthalidone increases hypomagnesemia risk (calibrated HR 1.57 vs hydrochlorothiazide) 3
Renal Function:
- Serum creatinine and eGFR: Expect transient increases, particularly in CKD patients 9, 6
- In the CLICK trial, reversible creatinine increases were common 6, 7
- Use with caution in severe renal impairment; may precipitate azotemia 5
Metabolic Parameters:
Glucose: Monitor for hyperglycemia and new-onset diabetes 2, 9, 6
- In ALLHAT, diabetes incidence was 11.8% with chlorthalidone vs 8.1% with lisinopril 2
Uric acid: Dose-related increases occur 2
- Gout is uncommon with doses ≤25 mg 2
- Monitor if patient has history of gout or hyperuricemia
Clinical Monitoring:
- Blood pressure: Measure just prior to next dose to assess trough effect 2
- Body weight: Track for volume status
- Orthostatic vital signs: Dizziness and orthostatic hypotension are more common with chlorthalidone 6, 7
Important Caveats
Chlorthalidone has higher potency and longer duration of action (24-72 hours) than hydrochlorothiazide 10, 11, 1, which explains both its greater efficacy and higher risk of electrolyte disturbances 3. The dose-response curve is relatively flat above 25 mg 12, 13, meaning higher doses increase adverse effects without proportional blood pressure benefit.
When combining with ACE inhibitors or ARBs, the hyperkalemia risk from these agents may partially offset chlorthalidone-induced hypokalemia, but careful monitoring remains essential 3.